Q1 EPS Forecast for Fennec Pharmaceuticals Lifted by Analyst

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Equities researchers at HC Wainwright increased their Q1 2025 EPS estimates for Fennec Pharmaceuticals in a research report issued on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.20). HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at ($0.28) EPS and FY2026 earnings at $0.63 EPS.

FENC has been the subject of several other reports. Stephens raised shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th. Wedbush restated an "outperform" rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Monday, March 10th.

Fennec Pharmaceuticals Trading Down 2.9 %

FENC stock traded down $0.19 on Thursday, hitting $6.32. 46,343 shares of the company's stock traded hands, compared to its average volume of 112,990. Fennec Pharmaceuticals has a 1-year low of $3.96 and a 1-year high of $11.49. The stock has a market cap of $174.19 million, a price-to-earnings ratio of -63.19 and a beta of 0.36. The stock has a fifty day moving average of $6.40 and a 200-day moving average of $5.64.

Remove Ads

Institutional Investors Weigh In On Fennec Pharmaceuticals

Large investors have recently made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. acquired a new position in Fennec Pharmaceuticals in the 4th quarter valued at approximately $97,000. Bank of America Corp DE increased its stake in Fennec Pharmaceuticals by 32.1% in the 4th quarter. Bank of America Corp DE now owns 35,827 shares of the company's stock valued at $226,000 after buying an additional 8,703 shares during the period. BNP Paribas Financial Markets increased its stake in Fennec Pharmaceuticals by 11.5% in the 4th quarter. BNP Paribas Financial Markets now owns 44,626 shares of the company's stock valued at $282,000 after buying an additional 4,610 shares during the period. Solas Capital Management LLC increased its stake in Fennec Pharmaceuticals by 17.0% in the 4th quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company's stock valued at $14,226,000 after buying an additional 327,383 shares during the period. Finally, MetLife Investment Management LLC acquired a new position in Fennec Pharmaceuticals in the 4th quarter valued at approximately $99,000. Institutional investors and hedge funds own 55.51% of the company's stock.

Insider Activity

In other news, Director Rosty Raykov sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $6.66, for a total transaction of $66,600.00. Following the sale, the director now owns 76,294 shares in the company, valued at $508,118.04. The trade was a 11.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 31,186 shares of company stock worth $203,389 over the last 90 days. 10.98% of the stock is owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.